Stock listing
Frankfurt:8EV TheraCryf PLC Aktie
German listing (Frankfurt) of TheraCryf PLC · home listing LSE:TCF
Follow TheraCryf PLC into a list and get an email when it puts out news.
Share price · FWB:8EV
€0.0005 EUR 0.0000 (0.0%)
Close on Oct 30, 2026
- Day range
- €0.0005 – €0.0005 EUROct 30, 2026
- Market cap
- €5.29M EURAt the close on Oct 30, 2026 · price × 10.58B shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:TCF · Home | 0.17p GBX (pence) | -0.005 (-2.9%) | 6,382,347 | 0.173p | 0.173p | 0.169p | 0.175p | Close on Oct 30, 2026 |
| Frankfurt:8EV | €0.0005 EUR | 0.0000 (0.0%) | — | €0.0005 | €0.0005 | €0.0005 | €0.0005 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:8EV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 22, 2026
Result of Annual General Meeting
Latest earnings call · Oct 20, 2026
Theracryf (LSE:TCF) — Update on the Ox-1 programme
Replay and transcript
Latest deck · Sep 7, 2026
Shareholder Meeting (September 2026)
Shareholder meeting · 14 slides
Calls
Replays
Theracryf (LSE:TCF) — Update on the Ox-1 programme
Tue, Oct 20, 2026 · 8:00 AM ET
Watch TranscriptTheracryf (LSE:TCF) — Final Results for the year ended 31 March 2026
Mon, Sep 28, 2026 · 8:00 AM ET
Watch TranscriptTheracryf (LSE:TCF) — Investor Presentation
Fri, Apr 24, 2026 · 5:00 AM ET
Watch Transcript
Latest news
Financings
Private placement of new ordinary shares (Placing Shares and Subscription Shares)
Aug 20, 2026 · US$1.43M
Announced: about £1.05M · GBX 0.18 a share · Turner Pope +1
Dealers: Turner Pope (lead), Singer Capital Markets (co-lead)
Buyers: Northern Standard Limited (138,888,888 Subscription Shares; 20.8% of Enlarged Share Capital following Admission); Dr Huw Jones (5,555,555 Subscription Shares); Toni Haenninen (via Borealito GmbH) (4,444,444 Subscription Shares); Dr Alastair Smith (13,888,888 Subscription Shares); Dr Nicholas Mallard (2,777,777 Subscription Shares); Dr Glen Clack (1,388,888 Subscription Shares); Dr Helen Kuhlman (3,333,333 shares)
Insiders: Certain PDMRs to subscribe for an aggregate 28,055,552 New Ordinary Shares through the PDMR Subscription
Use of proceeds: Complete clinic-enabling programme for Ox-1 addiction asset, apply for Phase 1 approval in Australia, and extend cash runway to end Q1 2027
Decks
Shareholder Meeting (September 2026)
Shareholder meeting · 14 slides · Sep 7, 2026
Investor Presentation (November 2025)
Investor deck · 21 slides · November 2025
Investor Presentation (February 2025)
Investor deck · 22 slides · February 2025
Investor Presentation (May 2024)
Investor deck · 12 slides · May 2024
TheraCryf PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 234 in all · newest Oct 22, 2026 · oldest 2007
- Calls
- 12 calls with a replay · 12 with a transcript · latest Oct 20, 2026
- Decks
- 15 decks · latest Sep 7, 2026
Where TheraCryf PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:TCF · Home listing | LSE | United Kingdom | GBX |
| Frankfurt:8EV · This page | Frankfurt | Germany | EUR |
Log in to ask 6ix AI your own questions about TheraCryf PLC.